Clinical and translational gastroenterology
Cure8 research brief
Why This Matters
Pulmonary nodules appear more frequently in people with Crohn’s disease and have distinct patterns over time. Knowing which factors predict nodule burden can help clinicians prioritize monitoring and interpret chest imaging in people with CD.
Who Should Pay Attention
Adults with Crohn’s disease; gastroenterologists and pulmonologists; researchers studying IBD extraintestinal manifestations.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This retrospective multicenter cohort study used real-world imaging data and inverse probability weighting to compare pulmonary nodule burden and dynamics between 2,009 patients with Crohn’s disease (CD) and 4,002 controls.
The authors report that patients with CD had higher counts of pulmonary nodules overall (including solid nodules) and distinct longitudinal changes: greater reductions in solid nodules and nodules <6 mm but somewhat faster growth of persistent nodules <6 mm.
Age and medication exposures—particularly adalimumab—were stronger predictors of nodule features than CD phenotype or extraintestinal manifestations. The analysis links adalimumab exposure with fewer non-solid and mid-sized (6–8 mm) nodules, and finds limited value of CD clinical phenotypes for predicting high-risk nodules.
The study emphasizes prioritizing age and medication history when stratifying nodule risk in patients with CD.
Keep In Mind
Findings come from a retrospective multicenter cohort and should be interpreted as associations. The summary is based on the PubMed abstract; consult the full paper for detailed methods and limitations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical and translational gastroenterology
AuthorsChangsheng Cai, He Gu, Chunyan Li +9 more
InstitutionDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center; Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of Digestive Disease; 160 Pu Jian Avenue, Shanghai 200127, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Plaque Psoriasis and Crohn’s Disease: Shared Biology, the IL-12/23 Pathway and Clinical Considerations
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.
Ustekinumab-induced Focal Segmental... : Journal of Nature and Science of Medicine - Ovid
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
Effectiveness of anti-TNF therapy after prior ustekinumab exposure in Crohn’s disease: A propensity-weighted cohort study
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...